Principal classes of anti-osteoporosis medications, such as bisphosphonates, estrogens, selective estrogen receptor modulators, and monoclonal antibodies, have shown anti-fracture efficacy (Chen and Sambrook, 2011). This evidence concerns the gene ESR1 and osteoporosis.